Atıf İçin Kopyala
Zeiser R., Polverelli N., Ram R., Hashmi S. K., Chakraverty R., Middeke J. M., ...Daha Fazla
The New England journal of medicine, cilt.385, ss.228-238, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
385
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1056/nejmoa2033122
-
Dergi Adı:
The New England journal of medicine
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
-
Sayfa Sayıları:
ss.228-238
-
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli:
Hayır
Özet
Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.